Document:

Amendment No. 1 to Distribution Agreement

 Exhibit 10.10 
  
 Pages where confidential treatment has been requested are stamped 
 “Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,” 
 and places where information has been redacted have been marked with (***). 
  
 AMENDMENT NO. 1 
 MC KESSON MEDICAL-SURGICAL INC. DISTRIBUTION AGREEMENT 
  
 This
Amendment No. 1 amends that distribution agreement between McKesson Medical-Surgical Inc. and Sound Surgical Technologies LLC dated as of June 14, 2004 (the “Distribution Agreement”) effective as of July 1, 2004 by adding the following
provisions. All capitalized terms used in this Amendment No. 1 and not otherwise defined herein shall have the meanings ascribed to them in the Distribution Agreement. 
  

	 	1.	Products shall include Seller’s VASER® System ultrasonic surgical system. 

  

	 	2.	Buyer shall distribute the VASER System only in connection with Seller’s Fee-Per-Procedure Agreement, as provided below. 

  

	 	3.	In promotion of the VASER System, Buyer will use its reasonable efforts to: 

  

	 	a.	promote the surgical procedure LipoSelectionSM
and the branding of the phrase “LipoSelection .... only by VASER” 

  

	 	b.	promote Seller’s VASER Fee-Per-Procedure program and agreement (the “VASER FPP Program”); and 

  

	 	c.	maintain proper use of Seller’s trademark VASER and its service mark LIPOSELECTION. 

  

	 	4.	In implementing distribution of the VASER System under the Distribution Agreement, the following will apply: 

  

	 	a.	Buyer’s sales force will qualify end-users in accordance with criteria established by Seller and communicated to Buyer and will use its reasonable effort to pre-sell to
qualified end-users Seller’s VASER FPP Program. 

  

	 	b.	When Buyer has achieved a strong level of interest in the VASER FPP Program in a qualified end-user (a “Lead”), Buyer will report that Lead to Seller with such information
as Seller reasonably may request. 

  

	 	c.	Buyer’s sales representative and Seller’s sales representative will cooperate in closing with each Lead a VASER FPP Program agreement (“FPP Agreement”) in the
form specified by Seller. Prior to closing, Seller will submit the name and other required information on the Lead to Partners Equity Capital Company (“PECC”) for credit approval. Such credit approval is required before Seller will sell a
VASER System to Buyer under the Distribution Agreement. 

  

	 	d.	Following PECC credit approval and receipt by Seller of a properly completed and signed FPP Agreement from a Lead, Seller will 

  

	 	i.	forward the FPP Agreement to PECC with an identification number beginning MCK-xxxxxx; 

  

	 	ii.	notify Buyer of the date the FPP Agreement was forwarded, the identification number, the name of the Lead/customer, and the term of and minimum under the FPP Agreement (as shown on
Attachment B); and 

  

	 	iii.	deliver the VASER System to the Lead/customer. 

  

	 	e.	Seller’s and Buyer’s respective sales representatives will cooperate in installing the System and performing required in-service training, and in obtaining and delivering
to Seller a properly completed and signed System acceptance document in the form specified by Seller. 

  

	 	f.	Seller will submit the signed acceptance document to PECC and will simultaneously deliver to Buyer by facsimile or e-mail in .PDF format a bill of sale for the relevant VASER System
in the form attached to and incorporated in this Amendment No. 1 as Attachment A, executed by Seller, and an invoice for the purchase price of the VASER System in the amount shown on Attachment B to this Amendment No. 1. The bill of

 
“Confidential Treatment Requested 
 and the Redacted Material has been 
 separately filed with the Commission.” 
  
 sale and invoice will carry the serial numbers of the principal components
of the VASER System, the name and address of the Lead/customer, and the FPP Agreement identification number. 
  

	 	g.	Promptly after receipt of the bill of sale and invoice, Buyer will deliver to PECC by facsimile a bill of sale in the form attached to and incorporated in this Amendment No. 1 as
Attachment C, executed by Buyer, and an invoice for the purchase price of the VASER System in the amount shown on Attachment B to this Amendment No. 1. The bill of sale and invoice will carry the serial numbers of the principal components of the
VASER System, the name and address of the Lead/customer, and the FPP Agreement identification number. 

  

	 	h.	PECC will pay Buyer’s invoice by immediate credit wire transfer to Buyer’s designated account. On the next business day (being any day except Saturday, Sunday and any day
on which national banks in the United States are closed) after receipt by Buyer of such funds, Buyer will pay Seller’s invoice by immediate credit wire transfer to Seller’s designated account. 

  

	 	5.	The 2% prompt payment discount provided by paragraph (d) of Subsection 4.1 of the Distribution Agreement shall not apply to VASER System transactions under this Amendment No. 1.

  

	 	6.	Buyer represents and covenants to Seller that, with respect to each purchase of a VASER System, it is purchasing the VASER System solely for resale to PECC and will not sell,
transfer, lease, rent, use or permit the use of, lien, charge or otherwise encumber the VASER System other than to transfer title to PECC. 

  

	 	7.	Buyer acknowledges and agrees that: 

  

	 	a.	each VASER System purchased by it is subject to all of the provisions, terms and conditions of (i) the FPP Agreement applicable to such VASER System and (ii) the Program Agreement
dated as of April 1, 2004 between Seller and PECC, as the same may be amended from time to time; 

  

	 	b.	Buyer retains no interest in any VASER System sold or transferred by it to PECC and has no right, obligation or other interest in or under any FPP Agreement related to any such
VASER System. 

  

	 	8.	Seller represents and warrants to Buyer, with respect to each VASER System sold to Buyer, that Seller has and will transfer to Buyer good and marketable title to the same free and
clear of any liens, charges or encumbrances except the related FPP Agreement. 

  

	 	9.	Except as modified by this Amendment No. 1, the Distribution Agreement shall remain in effect in accordance with its terms. 

  
 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the day and
year first above written. 
  

							
	(“Buyer”)	 	(“Seller”)
	 MCKESSON MEDICAL-SURGICAL INC.
	 	SOUND SURGICAL TECHNOLOGIES LLC
				
	By:	 	  

	 	By:	 	  

	Title:	 	  

	 	Title:	 	  

	Date:	 	  

	 	Date:	 	  

 “Confidential Treatment Requested 
 and the Redacted Material has been 
 separately filed with the Commission.”

  
 Addendum A 
  
 Conditional Bill of Sale 
  
 Subject to receipt by Sound Surgical Technologies LLC, a Colorado limited liability company
(“SST”) of payment of the consideration provided for pursuant to Amendment No. 1 to that Distribution Agreement dated as of June 14, 2004 between SST and McKesson Medical-Surgical Inc. (“McKesson”), the sufficiency of which SST
acknowledges, SST transfers and sells to McKesson the following equipment located at the address stated: 
  

							
	 EQUIPMENT
	    	 	  	 ADDRESS

			
	 VASER® Amplifier
	    	 Serial No. _____________
	  	 Name ___________________________________

	 	    	 	  	 
	 VentXTM Console
	    	 Serial No. _____________
	  	 Address _________________________________

	 	    	 	  	 
	 Precision Fluid
	    	 	  	 Address _________________________________

	 Management System
	    	 Serial No. _____________
	  	 
	 	    	 	  	 City/State/Zip _____________________________

  
 Ancillary instruments 
  
 SST warrants that it has and hereby conveys to McKesson good and marketable title to the
equipment free and clear of all liens, charges and encumbrances except that Fee-Per-Procedure Agreement dated as of                     ,
200    , bearing identification number MCK-                        . 
  
 Executed at Louisville, Colorado this         
day of             , 200    . 
  

			
	 Sound Surgical Technologies LLC

		
	 By
	 	  

	 Name
	 	  

	 Title
	 	  

 
“Confidential Treatment Requested 
 and the Redacted Material has been 
 separately filed with the Commission.” 
  
 Addendum B 
  
 PRICE SCHEDULE 
  

									
	 VASER FPP Program
 Agreement
Term/Minimum

	  	 Price from Seller
 to Buyer(1)

	 	 	 Price from Buyer
 to PECC

	 
	 36 months/3 per mo./$(***)
	  	$	(	***)	 	$	(	***)
	 36 months/4 per mo./$(***)
	  	$	(	***)	 	$	(	***)
			
	 48 months/3 per mo./$(***)
	  	$	(	***)	 	$	(	***)
	 48 months/4 per mo./$(***)
	  	$	(	***)	 	$	(	***)
			
	 90 day deferred payments
	  	 	 	 	 	 	 	 
	 36 months/3 per mo./$(***)
	  	$	(	***)	 	$	(	***)
	 36 months/4 per mo./$(***)
	  	$	(	***)	 	$	(	***)
			
	 48 months/3 per mo./$(***)
	  	$	(	***)	 	$	(	***)
	 48 months/4 per mo./$(***)
	  	$	(	***)	 	$	(	***)

	(1)	Price from Seller to Buyer equals (***) times (the price from Buyer to PECC minus $(***) documentation fee charged 

	 	by PECC). 

 “Confidential Treatment Requested 
 and the Redacted Material has been 
 separately filed with the Commission.”

  
 Addendum C 
  
 Conditional Bill of Sale 
  
 Subject to receipt by McKesson Medical-Surgical Inc. (“McKesson”) of payment of the
consideration provided for pursuant to that Program Agreement dated as of April 1, 2004 between Sound Surgical Technologies LLC and Partners Equity Capital Company (“PECC”), the sufficiency of which McKesson acknowledges, McKesson
transfers and sells to PECC the following equipment located at the address stated: 
  

							
	 EQUIPMENT
	    	 	  	 ADDRESS

			
	 VASER® Amplifier
	    	 Serial No. _____________
	  	 Name ___________________________________

	 	    	 	  	 
	 VentXTM Console
	    	 Serial No. _____________
	  	 Address _________________________________

	 	    	 	  	 
	 Precision Fluid
	    	 	  	 Address _________________________________

	 Management System
	    	 Serial No. _____________
	  	 
	 	    	 	  	 City/State/Zip _____________________________

  
 Ancillary instruments 
  
 McKesson warrants that it has and hereby conveys to PECC good and marketable title to the
equipment free and clear of all liens, charges and encumbrances except that Fee-Per-Procedure Agreement dated as of                     ,
200    , bearing identification number
MCK-                                . 
  
 Executed at Richmond, Virginia this         
day of             , 200    . 
  

			
	 MCKESSON MEDICAL-SURGICAL INC.

		
	 By
	 	  

	 Name
	 	  

	 TitleContribution Agreement

 Exhibit 10.11 
  
 CONTRIBUTION AGREEMENT 
  
 THIS AGREEMENT (this “Agreement”), dated as of April 1, 2003 (the “Effective Date”) between
Thomas J. Bogle, (“Contributor”), and Sound Surgical Technologies LLC, a Colorado limited liability company (the “Company”). 
  
 RECITALS: 
  
 A. Contributor is the sole member of Sound Surgical Sales, LLC, a Colorado limited liability company (the “Sound Surgical
Sales”); 
  
 B. Contributor desires to
contribute all of his right, title and interest as a member and manager in Sound Surgical Sales (the “Interest”) to the Company in exchange for 61 Units of Membership Interest in the Company (the
“Units”) on the terms and conditions contained herein. 
  
 C. Contributor will contribute 36 of the Units to Tom Bogle & Associates (“TBA”), a general partnership of which Contributor is a general partner and the other general partners are L. Randy
Billingsley, and Thomas Tierney. 
  
 NOW, THEREFORE, in
consideration of the mutual covenants herein contained and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, Contributor and Company agree as follows:

  
 Article I 
 Definitions 
  
 All capitalized terms shall have the meanings given them in the Operating Agreement of Sound Surgical Technologies LLC (the “Operating
Agreement”). 
  
 Article II

 Contribution and Acceptance 
  
 1. Amendment of the Operating Agreement of Sound Surgical Sales. The Contributor, as sole member of Sound Surgical Sales, hereby adopts the following
amendment to the operating agreement of Sound Surgical Sales to be effective immediately before the Effective Date: 
  
 The Member’s membership interest in Sound Surgical Sales, LLC including the right to participate in management (the “Membership
Interest”) is transferable either voluntarily or by operation of law. In the event of the transfer of the Member’s entire Membership Interest, the transferee shall succeed to all the Member’s rights as a member in Sound Surgical
Sales, LLC. Upon transfer of Member’s Membership Interest, the transferee shall be admitted as a member of Sound Surgical Sales without further action. 

 2. Contributor’s Contribution of Interest. Contributor hereby assigns, transfers and delivers to the
Company the Interest in exchange for the Units and the Company hereby accepts the Contribution of the Interest in exchange for the Units. The Company accepts the contribution. The Parties agree that the fair market value of the Interest as of the
Effective Date is $503,250. 
  
 3. Obligations of the Parties.

  
 3.1 The Contributor agrees to be bound by the Operating Agreement and agrees
to assume all of the obligations of membership with respect to the Units arising after the Effective Date. Sound Surgical Sales shall take the amount paid to it by the Company for Commissions and other liabilities listed in subsections 1.7 and 1.9
of Article III. The balance of any amounts paid as Commissions to Sound Surgical shall be paid to the Contributor. 
  
 3.2 The computers described on Schedule A are subject to computer leases. The Company understands that such leases will continue to be obligations of Sound Surgical Sales
and that Contributor shall not be responsible for them after the Effective Date. 
  
 Article III 
 Representations and Warranties 
  
 1. Contributor’s Representations and Warranties. The Contributor
represents and warrants to Company that to the best of his knowledge and belief as of the Effective Date: 
  
 1.1 The Contributor understands and acknowledges that the Units may constitute securities and have not been and are not contemplated to be registered under the federal Securities Act of 1933 (the “33 Act”)
or any state securities law. Except as provided in article IV, the Units cannot be offered for sale, sold, transferred, assigned, pledged, hypothecated or otherwise disposed of unless there is an effective registration statement or other
qualification relating to such securities under the 33 Act and any applicable state securities laws or unless the Company receives an opinion of counsel satisfactory to the Company that such registration or other qualification is not required in
connection with such offer, transfer, sale, transfer, assignment, pledge, hypothecation or other disposition. The Company has no obligation to register or to cooperate in the registration of such securities. Contributor represents to the Company and
to each other Member that such Member is an “accredited investor” as defined in Rule 501(a) under the 33 Act and that, except as provided in Article IV, the Contributor’s contribution of the Interest in exchange for the Units is
solely for the Contributor and not directly or indirectly for or for the benefit of others and is purchased for investment purposes and not for resale. Notwithstanding the foregoing, the parties understand that Contributor will contribute a
membership interest in the Company consisting of 36 Units to TBA, a general partnership as described in Article IV below consisting of the Contributor, L. Randy Billingsley, and Thomas Tierney. 
  
 1.2 Sound Surgical Sales is a limited liability company, duly organized, validly existing and
in good standing under the laws of Colorado and qualified to do business in California and Washington, and has the power and authority to own all of its property and conduct its business. 
  

 2 

 1.3 The Contributor is the sole member of Sound Surgical Sales; no other person has a right or option to acquire a
membership interest in Sound Surgical Sales; and the interest in Sound Surgical Sales being transferred by the Contributor pursuant to this Agreement comprise all of the equity interests of any class, kind or type in Sound Surgical Sales.

  
 1.4 The Contributor has all requisite power and authority to execute and
deliver this Agreement. This Agreement, when executed by the Contributor, constitutes the legal, valid and binding obligation of the Contributor, enforceable against the Contributor in accordance with its terms, except as such enforceability may be
limited by bankruptcy, insolvency or similar laws and by equitable principles. Neither the execution of this Agreement nor the consummation by the Contributor of the transactions contemplated hereby will (i) constitute a violation of the limited
liability agreement of Sound Surgical Sales, or any law, statute, regulation, ordinance, judgment, decree or order applicable to the Contributor or Sound Surgical Sales and of which the Contributor has actual knowledge, (ii) result in the creation
of any lien, charge or encumbrance upon the Interest or any part thereo or upon any asset of Sound Surgical Sales, or (iii) result in the breach of or default under any agreement or instrument to which the Contributor or Sound Surgical Sales, as the
case may be, is a party. 
  
 1.5 There is no action, suit or proceeding before any
court or governmental or other regulatory or administrative agency, commission or tribunal or any arbitration pending or threatened against the Contributor or Sound Surgical Sales that, if determined adversely to Sound Surgical Sales or the
Contributor, would reasonably be expected to interfere in any material respect with the ability of such the Contributor to perform his obligations under this Agreement or materially and adversely affect the value of the Interest to be contributed to
the Company. 
  
 1.6 No election has been filed to treat Sound Surgical Sales as a
corporation for federal income tax purposes. 
  
 1.7 Sound Surgical Sales is not
subject to any obligations or liabilities, except for (i) obligations for commissions due to employees in an amount equal to the commissions owed to Sound Surgical Sales by the Company, (ii) Employment taxes with respect to the compensation to be
paid by way of commissions, and (ii) customary unsecured trade debt which does not exceed $1,000.00 as of the Effective Date. Contributor warrants to Company that, subject to payment to Sound Surgical Sales by the Company on o before April 3, 2003
of commissions due Sound Surgical Sales as of March 31, 2003, Contributor will pay or ensure that Sound Surgical Sales pays on or before April 7, 2003 all commissions and other compensation, if any, due to employees of Sound Surgical Sales as of the
Effective Date and all employment taxes due with respect to such commissions and other compensation, and that the Company will not be required to make any additional contribution or loan to Sound Surgical Sales to fund any such payment. 

 
 1.8 As of the Effective Date, Sound Surgical Sales has no employees and has a liability
with respect to unpaid commissions not in excess of $ 25,0000 and with respect to employment taxes relating thereto. 
  
 1.9 As of the Effective Date, Sound Surgical Sales owns the real and personal property set forth on Exhibit “A” hereto free and clear of any liens, charges or
encumbrances. 
  

 3 

 2. Company’s Representations and Warranties. Company represents and warrants to Contributor that as of
the date hereof: 
  
 2.1 The Company is a limited liability company, duly
organized, validly existing and in good standing under the laws of Colorado and qualified to do business in Colorado, Arizona, Florida, Nevada and Ohio, and has the power and authority to own all of its property and conduct its business. 

 
 2.2 All actions of the Members, Managers and Management Committee (including, but not
limited to, the approval of the Management Committee with respect to the issuance of the Units to the Contributor by the Company and the waiver of any Preemptive rights with respect to the contribution) necessary for the consummation by the Company
of the transactions contemplated in this Agreement have been duly taken and are in effect, and the Company has all requisite power and authority to execute and deliver this Agreement. This Agreement, when executed on behalf of the Company,
constitutes the legal, valid and binding obligations of the Company, enforceable against the it in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency or similar laws and by equitable principles. Neither
the execution of this Agreement nor the consummation by the Company of the transactions contemplated hereby will (i) constitute a violation of the Operating Agreement, or any law, statute, regulation, ordinance, judgment, decree or order applicable
to the Company and of which the Company has actual knowledge, or (ii) result in the breach of or default under any agreement or instrument to which the Company is a party. 
  
 2.3 There is no action, suit or proceeding before any court or governmental or other regulatory or administrative agency, commission or
tribunal or any arbitration pending or threatened against the Company that, if determined adversely to the Company would reasonably be expected to interfere in any material respect with the ability of such Company to perform its obligations under
this Agreement. 
  
 2.4 No election has been filed to treat the Company as a
corporation for federal income tax purposes. 
  
 Article
IV 
  
 Contribution of the Units to Bogle
Associates 
  
 1. Contribution. Upon receipt of the Units,
Contributor will contribute 36 Units to TBA, a general partnership with its chief executive office in Colorado. Contributor is a general partner of TBA, and will receive a credit to his capital account in TBA for the value of the 36 Units
Contributed. This Article is for information purposes only and neither this Article nor any contribution of Units to TBA constitutes a requirement or obligation of or consideration for any obligation in this Agreement. Notwithstanding the foregoing,
the Company shall be entitled to rely on the representations in paragraph 2, below, in determining whether or not to consent to the contribution of Units referred to in this paragraph 1. 
  
 2. Representations of Contributor as a Partner in TBA. The Contributor represents that he is a general partner of TBA and in
such capacity understands and acknowledges that the Units may be securities and have not been and are not contemplated to be registered under the federal 
  

 4 

 Securities Act of 1933 (the “33 Act”) or any state securities law. The Units cannot be offered for sale, sold,
transferred, assigned, pledged, hypothecated or otherwise disposed of unless there is an effective registration statement or other qualification relating to such securities under the 33 Act and any applicable state securities laws or unless the
Company receives an opinion of counsel satisfactory to the Company that such registration or other qualification is not required in connection with such offer, transfer, sale, transfer, assignment, pledge, hypothecation or other disposition. The
Company has no obligation to register or to cooperate in the registration of such securities. Contributor represents to each other Member and to the Company that the partners of TBA are “accredited investors” as defined in Rule 501(a)
under the 33 Act and that, except as provided in the last sentence of this Section 1.1, the Contributor’s contribution of the Interest in exchange for the Units is solely for such Member and not directly or indirectly for or for the benefit of
others and is purchased for investment purposes and not for resale. 
  
 3.
Condition Precedent to Contribution. The Company shall not permit the contribution of the Units to TBA unless each of the Contributor, L. Randy Billingsley, and Thomas Tierney shall have satisfactorily completed a Request for Consent to Transfer
of Membership Units in a form acceptable to the Company. 
  
 Article V 
 Miscellaneous 
  
 1. Notices. All notices, requests and other communications hereunder must be in writing and will be deemed to have been duly
given only if delivered personally, by overnight courier, or by facsimile transmission to the parties at the following addresses or facsimile numbers: 
  
 If to Contributor, to: 
  
 Thomas J. Bogle 
 25 Downing Street, Unit 103

 Denver, CO 80209 
 Facsimile
No. (303) 926-8615 
  
 with a copy, which shall not constitute
notice, to: 
  
 Robert R. Keatinge, Esq. 
 Holland and Hart, LLP 
 555 17th Street, Suite 3200 
 Denver, CO 80202 
 Facsimile No.: (303) 295-8261 
  
 If to the Company, to: 
  
 Sound Surgical Technologies LLC 
 1300 Plaza
Court North Suite 103 
 Lafayette, CO 80026-1467 
 Attn: Douglas Foote 
 Facsimile No. (303) 926-8615 
  

 5 

 All such notices, requests and other communications will (i) if delivered personally or by overnight courier to the
address as provided in this Section, be deemed given upon delivery, and (ii) if delivered by facsimile transmission to the facsimile number as provided in this Section, be deemed given upon receipt. Any party from time to time may change its
address, facsimile number or other information for the purpose of notices to that party or copies of notices by giving notice specifying such change to the other parties hereto. 
  
 2. Entire Agreement. This Agreement, including all schedules and exhibits hereto, the supersede all prior discussions and
agreements between the parties with respect to the subject matter hereof and thereof, and contain the sole and entire agreement between the parties hereto with respect to the subject matter hereof and thereof. 
  
 3. Waiver. Any term or condition of this Agreement may be waived at any time by
the party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such term or condition. No waiver by any party of any term or
condition of this Agreement, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. All remedies, either under this Agreement or by applicable
law or otherwise afforded, will be cumulative and not alternative. 
  
 4.
Modification. This Agreement may be amended, supplemented or modified only by a written instrument duly executed by or on behalf of each party hereto. 
  
 5. Successors and Assigns. The terms and provisions of this Agreement are intended solely for the benefit of each party hereto
and their respective successors or permitted assigns, and it is not the intention of the parties to confer third-party beneficiary rights upon any other person. Subject to the terms of Section 6.10 hereof, this Agreement is binding upon, inures to
the benefit of and is enforceable by the parties hereto and their respective successors and assigns. 
  
 6. Interpretation. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law, and if the rights or obligations of any party hereto under this
Agreement will not be materially and adversely affected thereby, (a) such provision will be fully severable, (b) this Agreement will be construed and enforced as if such illegal, invalid or unenforceable provision had never comprised a part hereof,
(c) the remaining provisions of this Agreement will remain in full force and effect and will not be affected by the illegal, valid or unenforceable provision or by its severance herefrom and (d) in lieu of such illegal, invalid or unenforceable
provision, there will be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable provision as may be possible. 
  
 7. Governing Law. This Agreement shall be governed by and construed in
accordance with the laws of the State of Colorado applicable to a contract executed and performed in such State, without giving effect to the conflicts of laws principles thereof. 
  

 6 

 8. Counterparts. This Agreement may be executed in any number of counterparts, and by facsimile signature,
each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
  
 9. Assignment. Neither party may assign or transfer its rights or obligations under this Agreement without the prior written consent of the other, which
consent may be granted or denied in the sole discretion of the party whose consent is sought. 
  
 IN WITNESS WHEREOF, Contributor and the Company have executed and delivered this Agreement as of the day and year first above written. 
  

					
	CONTRIBUTOR
	
	 / Thomas J. Bogle /

	 Thomas J. Bogle

	
	THE COMPANY:
	
	Sound Surgical Technologies LLC
	 A Colorado limited liability company

			
	 	 	 By:
	 	 / Donald B. Wingerter, Jr. /

	 	 	 	 	 Donald B. Wingerter, Jr.

	 	 	 	 	 Chief Executive Officer and Manager

			
	 	 	 By:
	 	 / Douglas D. Foote /

	 	 	 	 	 Douglas D. Foote

	 	 	 	 	 Chief Financial Officer and Manager

  

 7 

 EXHIBIT A 
  
 Property of Sound Surgical Sales 
  
 Twelve Computers subject to leases. 
  

All Data contained on those computers and other information and records of Sound Surgical Sales.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00076-of-00352.parquet"}]]